Figure 3
Dose–response curve of RA283 on LRRK2 Ser935 dephosphorylation in control and LRRK2 G2019S PD patient LCLs. (A) Representative western blots of healthy control and LRRK2 G2019S patient-derived LCLs treated for 24 h treatment with Compound RA283. (B) Quantification of western blots demonstrated that Compound RA283 decreased LRRK2 pSer935 levels at all doses tested. Data are mean ± SEM. (*p < 0.001, determined by one-way ANOVA with a Tukey’s post-hoc comparison). n = 3 biological replicates (6 cell lines total), each performed in technical replicate. Full blots available in Supplemental Figs. S9 and S10.
